Advertisement
BMY vs NVS
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- BMY raised its full-year 2026 revenue guidance to $49.0–$50.0 billion following strong second-quarter results driven by a 15% increase in its Growth Portfolio.
- NVS reaffirmed its 2026 guidance after reporting modest 3% revenue growth, while facing multiple late-stage trial setbacks in September 2026.
- Recent clinical updates favored BMY with positive two-year Sotyktu data in psoriatic arthritis, whereas NVS halted an ALS program and reported failures in cardiovascular and neuromuscular trials.
- BMY shares have shown resilience with a 1-year return near 45%, compared with NVS delivering approximately 14% over the same period amid greater volatility.
- Both companies maintain attractive dividend yields above 2%, supported by substantial cash flows from established pharmaceutical franchises.
- Sector exposure remains concentrated in oncology and specialty medicines for both, with BMY demonstrating more consistent recent momentum in its growth assets.
Introduction
This comparison examines BMY (Bristol-Myers Squibb) and NVS (Novartis), two leading pharmaceutical companies with diversified portfolios in oncology, immunology, and specialty therapeutics. Investors and traders seeking to understand relative performance, pipeline momentum, and market positioning in the healthcare sector may find this analysis relevant. The article focuses on verifiable developments from recent weeks, including earnings updates and clinical trial outcomes, to provide a balanced view of how each stock has responded to current market conditions without offering forward-looking predictions.
BMY Overview and Recent Performance
Bristol-Myers Squibb develops and commercializes medicines primarily in oncology, hematology, immunology, and cardiovascular disease. In recent market activity, the stock has traded near $63 with a market capitalization of approximately $129 billion. Second-quarter 2026 revenues reached $13.0 billion, up 6% year over year, propelled by 15% growth in the Growth Portfolio that includes Opdivo, Reblozyl, and Camzyos. The company raised its full-year 2026 revenue outlook to a range of $49.0–$50.0 billion and non-GAAP EPS guidance to $6.75–$7.00. Recent weeks featured positive Phase 3 data for Sotyktu in psoriatic arthritis and continued pipeline advancement, supporting sentiment despite legacy portfolio pressures from patent expirations.
NVS Overview and Recent Performance
Novartis focuses on innovative medicines in oncology, neuroscience, and immunology, with key products including Kisqali and Cosentyx. The stock has recently traded around $140, corresponding to a market capitalization near $266 billion. Second-quarter 2026 net sales totaled $14.4 billion, reflecting 3% growth, with the company reaffirming its full-year guidance for low single-digit sales expansion. Recent market activity included a positive Phase 3 outcome for remibrutinib in multiple sclerosis early in the period, offset by September setbacks including the discontinuation of an ALS candidate and missed endpoints in cardiovascular and neuromuscular studies. These developments contributed to price volatility while the broader portfolio continued to generate stable cash flows.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of high-performing AI trading bots from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance metrics tailored to evolving market conditions. Only those demonstrating the strongest suitability for current environments earn placement in the trending section, which features bots with diverse statistics including win rates, drawdowns, and return profiles across multiple asset classes. Traders can explore these options to identify automated approaches aligned with specific risk tolerances and objectives. Visit the Trending AI Robots page for detailed listings and performance data.
Head-to-Head Comparison
BMY and NVS operate in overlapping therapeutic areas yet differ in scale and recent trajectory. NVS maintains a larger market capitalization and broader global footprint, while BMY has delivered more pronounced recent revenue acceleration through its Growth Portfolio. Both face generic competition on legacy products, but BMY offset these pressures more effectively in the latest quarter by raising guidance. Pipeline momentum contrasts sharply: BMY reported consistent positive clinical readouts in recent weeks, whereas NVS encountered multiple late-stage disappointments. Market sentiment reflects these dynamics, with BMY exhibiting steadier price behavior amid sector rotation and NVS experiencing sharper swings tied to trial outcomes. Dividend sustainability appears comparable given both firms’ robust free-cash-flow generation.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent earnings momentum, pipeline catalysts, and relative positioning, Tickeron’s AI models currently assign a higher probabilistic preference to BMY over NVS. The stock’s ability to raise guidance alongside supportive clinical data in recent weeks contributes to this assessment, while NVS contends with greater near-term uncertainty from trial results. This evaluation remains probabilistic and subject to ongoing market developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and NVS is a Buy.
BMY | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 11 | |
SMR RATING 1..100 | 22 | 33 | |
PRICE GROWTH RATING 1..100 | 44 | 56 | |
P/E GROWTH RATING 1..100 | 66 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 45 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (41). This means that NVS’s stock grew somewhat faster than BMY’s over the last 12 months.
NVS's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (81). This means that NVS’s stock grew significantly faster than BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is in the same range as NVS (33). This means that BMY’s stock grew similarly to NVS’s over the last 12 months.
BMY's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as NVS (56). This means that BMY’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (66). This means that NVS’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | NVS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 55% | 3 days ago 38% |
| Stochastic ODDS (%) | 3 days ago 59% | 3 days ago 41% |
| Momentum ODDS (%) | 3 days ago 56% | 3 days ago 48% |
| MACD ODDS (%) | 3 days ago 39% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 40% |
| Advances ODDS (%) | 3 days ago 56% | 3 days ago 54% |
| Declines ODDS (%) | 5 days ago 53% | 19 days ago 43% |
| BollingerBands ODDS (%) | 3 days ago 60% | 3 days ago 33% |
| Aroon ODDS (%) | 3 days ago 53% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- NVS’s TA Score: 4 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.32% price change this week, while NVS (@Pharmaceuticals: Major) price change was +3.63% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.05%. For the same industry, the average monthly price growth was -5.35%, and the average quarterly price growth was +17.52%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.05% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +2.21% | ||
| AMGN - BMY | 57% Loosely correlated | +2.11% | ||
| PFE - BMY | 57% Loosely correlated | +0.92% | ||
| NVS - BMY | 55% Loosely correlated | +1.32% | ||
| GSK - BMY | 53% Loosely correlated | -0.83% | ||
| ABBV - BMY | 51% Loosely correlated | -0.29% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.